October 23, 2014 4:59 AM ET

Biotechnology

Company Overview of Avicena Group Inc

Company Overview

Avicena Group, Inc., a biotechnology company, develops central nervous system therapeutics for neurodegenerative diseases. The company's technologies have applications in both pharmaceuticals and dermaceuticals. Its pharmaceutical program centers on rare neurological disorders (orphan diseases). The company plans to initiate a Phase III trial in Huntington's disease and a confirmatory Phase III trial in amyotrophic lateral sclerosis to accompany the ongoing NIH Phase III trial in Parkinson's disease. The company focuses on developing orphan drug products for neurological diseases, such as Amyotrophic Lateral Sclerosis (ALS), Huntington’s, and Creatine Transporter Defect; as well as cosmeceut...

228 Hamilton Avenue

3rd floor

Palo Alto, CA 94301

United States

Founded in 1989

3 Employees

Phone:

415-397-2880

Fax:

415-397-2898

Key Executives for Avicena Group Inc

Chairman and Chief Executive Officer
Age: 46
Co-Founder
Acting Chief Financial Officer
Age: 60
Vice President of Marketing & Business Strategy
Age: 54
Financial Strategic & Operational Advisor and Director
Age: 55
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Genome Corp. United States
Akceli Inc. United States
Primrose Therapeutics, Inc. United States
PharmaPrint Inc. United States
Palmera Holdings, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Avicena Group Inc, please visit www.avicenagroup.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.